{"name":"MERZ","slug":"merz","ticker":"","exchange":"","domain":"merz.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1970-01-01","label":"Inbrija first approved","drug":"Inbrija","drugSlug":"levodopa","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Xeomin first approved","drug":"Xeomin","drugSlug":"incobotulinumtoxina","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-02-03","label":"Inbrija patent expiry (Method of Use)","drug":"Inbrija","drugSlug":"levodopa","type":"patent_expiry","sentiment":"negative"},{"date":"2032-11-16","label":"Inbrija patent expiry (Formulation)","drug":"Inbrija","drugSlug":"levodopa","type":"patent_expiry","sentiment":"negative"},{"date":"2032-11-16","label":"Inbrija patent expiry (Formulation)","drug":"Inbrija","drugSlug":"levodopa","type":"patent_expiry","sentiment":"negative"},{"date":"2032-11-16","label":"Inbrija patent expiry (Formulation)","drug":"Inbrija","drugSlug":"levodopa","type":"patent_expiry","sentiment":"negative"},{"date":"2032-11-16","label":"Inbrija patent expiry (Formulation)","drug":"Inbrija","drugSlug":"levodopa","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-21","label":"Inbrija patent expiry (Method of Use)","drug":"Inbrija","drugSlug":"levodopa","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"oncology","drugs":[{"name":"Hyaluronic acid filler/IMD1 basic","genericName":"Hyaluronic acid filler/IMD1 basic","slug":"hyaluronic-acid-filler-imd1-basic","indication":"Facial wrinkles and folds correction","status":"marketed"},{"name":"Placebo 4-weeks","genericName":"Placebo 4-weeks","slug":"placebo-4-weeks","indication":"Other","status":"phase_3"},{"name":"Contractubex","genericName":"Contractubex","slug":"contractubex","indication":"Other","status":"marketed"},{"name":"IncobotulinumtoxinA (75 Units)","genericName":"IncobotulinumtoxinA (75 Units)","slug":"incobotulinumtoxina-75-units","indication":"Cervical dystonia","status":"phase_3"},{"name":"NAFT500 (adult)","genericName":"NAFT500 (adult)","slug":"naft500-adult","indication":"Temporary improvement of moderate to severe glabellar lines (frown lines) in adults","status":"marketed"},{"name":"NAFT500 (pediatric)","genericName":"NAFT500 (pediatric)","slug":"naft500-pediatric","indication":"Tinea pedis (athlete's foot) in pediatric patients","status":"marketed"},{"name":"NAFT600 (adult)","genericName":"NAFT600 (adult)","slug":"naft600-adult","indication":"Temporary improvement of moderate to severe glabellar lines (frown lines) in adults","status":"marketed"},{"name":"NAFT600 (pediatric)","genericName":"NAFT600 (pediatric)","slug":"naft600-pediatric","indication":"Pediatric spasticity","status":"marketed"},{"name":"Naftin 1% Cream","genericName":"Naftin 1% Cream","slug":"naftin-1-cream","indication":"Tinea pedis (athlete's foot)","status":"phase_3"},{"name":"Naftin Cream","genericName":"Naftin Cream","slug":"naftin-cream","indication":"Other","status":"marketed"},{"name":"OnabotulinumtoxinA (Vistabel®)","genericName":"OnabotulinumtoxinA (Vistabel®)","slug":"onabotulinumtoxina-vistabel","indication":"Blepharospasm","status":"phase_3"},{"name":"Pantovigar","genericName":"Pantovigar","slug":"pantovigar","indication":"Other","status":"phase_2"},{"name":"Placebo 2-weeks","genericName":"Placebo 2-weeks","slug":"placebo-2-weeks","indication":"Other","status":"phase_3"},{"name":"Xeomin","genericName":"INCOBOTULINUMTOXINA","slug":"incobotulinumtoxina","indication":"Chronic sialorrhea","status":"marketed"},{"name":"incobotulinumtoxinA (Xeomin)","genericName":"incobotulinumtoxinA (Xeomin)","slug":"incobotulinumtoxina-xeomin","indication":"Blepharospasm","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"NAFT-500","genericName":"NAFT-500","slug":"naft-500","indication":"Fungal skin infection (specific indication under phase 3 evaluation)","status":"phase_3"},{"name":"NAFT-600 ( naftin 2 % gel )","genericName":"NAFT-600 ( naftin 2 % gel )","slug":"naft-600-naftin-2-gel","indication":"Fungal skin infections (dermatophyte infections, tinea pedis, tinea cruris, tinea corporis)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Inbrija","genericName":"LEVODOPA","slug":"levodopa","indication":"Parkinson's disease","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NT 201","genericName":"NT 201","slug":"nt-201","indication":"Temporary improvement of moderate to severe glabellar lines (frown lines between eyebrows)","status":"marketed"}]}],"pipeline":[{"name":"Hyaluronic acid filler/IMD1 basic","genericName":"Hyaluronic acid filler/IMD1 basic","slug":"hyaluronic-acid-filler-imd1-basic","phase":"marketed","mechanism":"Hyaluronic acid filler provides volumization and hydration to facial tissues by integrating into the dermis and binding water molecules.","indications":["Facial wrinkles and folds correction","Lip augmentation","Facial volume restoration"],"catalyst":""},{"name":"Inbrija","genericName":"LEVODOPA","slug":"levodopa","phase":"marketed","mechanism":"Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination.","indications":["Parkinson's disease","Parkinsonism","Postencephalitic parkinsonism"],"catalyst":""},{"name":"NT 201","genericName":"NT 201","slug":"nt-201","phase":"marketed","mechanism":"NT 201 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to temporarily paralyze muscles.","indications":["Temporary improvement of moderate to severe glabellar lines (frown lines between eyebrows)","Temporary improvement of forehead lines and crow's feet"],"catalyst":""},{"name":"Placebo 4-weeks","genericName":"Placebo 4-weeks","slug":"placebo-4-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Contractubex","genericName":"Contractubex","slug":"contractubex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IncobotulinumtoxinA (75 Units)","genericName":"IncobotulinumtoxinA (75 Units)","slug":"incobotulinumtoxina-75-units","phase":"phase_3","mechanism":"IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Glabellar lines (dynamic wrinkles)","Crow's feet"],"catalyst":""},{"name":"NAFT-500","genericName":"NAFT-500","slug":"naft-500","phase":"phase_3","mechanism":"NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions.","indications":["Fungal skin infection (specific indication under phase 3 evaluation)"],"catalyst":""},{"name":"NAFT-600 ( naftin 2 % gel )","genericName":"NAFT-600 ( naftin 2 % gel )","slug":"naft-600-naftin-2-gel","phase":"phase_3","mechanism":"Naftin is an allylamine antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.","indications":["Fungal skin infections (dermatophyte infections, tinea pedis, tinea cruris, tinea corporis)"],"catalyst":""},{"name":"NAFT500 (adult)","genericName":"NAFT500 (adult)","slug":"naft500-adult","phase":"marketed","mechanism":"NAFT500 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Temporary improvement of moderate to severe glabellar lines (frown lines) in adults"],"catalyst":""},{"name":"NAFT500 (pediatric)","genericName":"NAFT500 (pediatric)","slug":"naft500-pediatric","phase":"marketed","mechanism":"NAFT500 is a naftifine hydrochloride topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase.","indications":["Tinea pedis (athlete's foot) in pediatric patients","Tinea cruris (jock itch) in pediatric patients","Tinea corporis (ringworm) in pediatric patients"],"catalyst":""},{"name":"NAFT600 (adult)","genericName":"NAFT600 (adult)","slug":"naft600-adult","phase":"marketed","mechanism":"NAFT600 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Temporary improvement of moderate to severe glabellar lines (frown lines) in adults","Temporary improvement of moderate to severe lateral canthal lines (crow's feet) in adults"],"catalyst":""},{"name":"NAFT600 (pediatric)","genericName":"NAFT600 (pediatric)","slug":"naft600-pediatric","phase":"marketed","mechanism":"NAFT600 is a botulinum toxin product used to reduce muscle contractions and treat movement disorders in pediatric patients.","indications":["Pediatric spasticity","Pediatric movement disorders"],"catalyst":""},{"name":"Naftin 1% Cream","genericName":"Naftin 1% Cream","slug":"naftin-1-cream","phase":"phase_3","mechanism":"Naftin (naftifine) is a topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.","indications":["Tinea pedis (athlete's foot)","Tinea cruris (jock itch)","Tinea corporis (ringworm)"],"catalyst":""},{"name":"Naftin Cream","genericName":"Naftin Cream","slug":"naftin-cream","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OnabotulinumtoxinA (Vistabel®)","genericName":"OnabotulinumtoxinA (Vistabel®)","slug":"onabotulinumtoxina-vistabel","phase":"phase_3","mechanism":"OnabotulinumtoxinA works by temporarily paralyzing muscles to treat various conditions.","indications":["Blepharospasm","Cervical dystonia","Focal spasticity","Hemifacial spasm","Severe primary axillary hyperhidrosis"],"catalyst":""},{"name":"Pantovigar","genericName":"Pantovigar","slug":"pantovigar","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo 2-weeks","genericName":"Placebo 2-weeks","slug":"placebo-2-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Xeomin","genericName":"INCOBOTULINUMTOXINA","slug":"incobotulinumtoxina","phase":"marketed","mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract.","indications":["Chronic sialorrhea","Upper limb spasticity in adults","Upper limb spasticity in pediatric patients (excluding cerebral palsy)","Cervical dystonia in adults","Blepharospasm in adults"],"catalyst":""},{"name":"incobotulinumtoxinA (Xeomin)","genericName":"incobotulinumtoxinA (Xeomin)","slug":"incobotulinumtoxina-xeomin","phase":"phase_3","mechanism":"IncobotulinumtoxinA is a botulinum toxin type A that works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contractions.","indications":["Blepharospasm","Cervical dystonia","Strabismus","Spasticity","Hemifacial spasm"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[{"drugName":"Inbrija","drugSlug":"levodopa","patentNumber":"RE43711","type":"Method of Use","expiryDate":"2029-02-03","territory":"US","genericFilings":[]},{"drugName":"Inbrija","drugSlug":"levodopa","patentNumber":"8685442","type":"Formulation","expiryDate":"2032-11-16","territory":"US","genericFilings":[]},{"drugName":"Inbrija","drugSlug":"levodopa","patentNumber":"8945612","type":"Formulation","expiryDate":"2032-11-16","territory":"US","genericFilings":[]},{"drugName":"Inbrija","drugSlug":"levodopa","patentNumber":"8545878","type":"Formulation","expiryDate":"2032-11-16","territory":"US","genericFilings":[]},{"drugName":"Inbrija","drugSlug":"levodopa","patentNumber":"9393210","type":"Formulation","expiryDate":"2032-11-16","territory":"US","genericFilings":[]},{"drugName":"Inbrija","drugSlug":"levodopa","patentNumber":"12458615","type":"Method of Use","expiryDate":"2033-10-21","territory":"US","genericFilings":[]}],"drugCount":19,"phaseCounts":{"marketed":10,"phase_3":8,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}